期刊
CLINICAL BIOCHEMISTRY
卷 72, 期 -, 页码 52-57出版社
PERGAMON-ELSEVIER SCIENCE LTD
DOI: 10.1016/j.clinbiochem.2019.08.008
关键词
-
Core Alzheimer's Disease (AD) biomarkers are the cerebrospinal fluid (CSF) proteins amyloid beta 42 and beta 40, and the tau proteins, total and phosphorylated. Their use is recommended by research guidelines for diagnostic purpose and for stratification of patients for clinical trials. However, novel potential biomarkers are needed, which can mirror risk factors and other different mechanisms of the disease, hopefully in less invasive biological fluids or matrices. Studies on blood, urine, saliva, tears gave promising results, and several novel molecules have been identified, as potential brain derived biomarkers, thanks to the development of novel ultrasensitive technologies. In this review, we discuss about advantages and limits of the classical CSF biomarkers of AD, as well as of novel CSF candidate biomarkers and recent promises from alternative matrices.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据